In an era characterized by macro headwinds and profound market volatility, the biotech industry continues to raise capital to fuel drug development, clinical trials, and innovation. Capital raising in challenging markets comes with additional risks, leading venture capital firms and crossover investors to identify creative, unconventional deal structures and strategies that are redefining the biotech investment landscape. Join Chen Yu, Founder & Managing Partner at TCGX, Matthew Young, Managing Director at Longitude Capital, Arsani William, CIO & Managing Partner at Logos Capital, and RBC’s Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion exploring how investors across the biotech ecosystem are navigating market complexity to put dollars to work creatively to manage risks, maximize rewards, and stimulate growth.
Dr. Yu is the founder and Managing Partner at TCGX. Prior to founding TCGX, Dr. Yu spent sixteen years as a Managing Partner at Vivo Capital. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including stints as the COO of Sagent Pharmaceuticals and CBO of China KangHui, both of which went public and were ultimately acquired. Dr. Yu has served on the board of over a dozen private/public companies, including Structure Therapeutics (NASDAQ: GPCR), Tarsus Pharmaceuticals (NASDAQ: TARS), AdaRx, Artios, Upstream Bio, Arbor Biotechnologies, Sagent Pharmaceuticals (NASDAQ: SGNT, acquired by Nichi-I-Ko), China Kanghui (NYSE:KH, acquired by Medtronic), Rempex (acquired by Medicines Company), Kala (NASDAQ:KALA), Nabriva (NASDAQ: NBRV), Surgical Specialties (acquired by GTCR), Sentre Heart (acquired by Atricure), and NKF Pharma (SHA: 603707). While at Vivo, he also led investments in Zai Labs (NASDAQ: ZLAB), RiverVision (acquired by Horizon), CRISPR Therapeutics (NASDAQ:CRSP), Intellia (NASDAQ: NTLA), Durata (acquired by Actavis), Precision Biosciences (NASDAQ: DTIL), Trauson (acquired by Stryker), and Revolution Medicines (NASDAQ:RVMD).
Dr. Yu also serves on the California Leadership Council for the Nature Conservancy and was previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.
Mr. Young is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina (ILMN) for $8 billion in 2021. From 2013 to 2019, Mr. Young held positions of increasing responsibility at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company, most recently as Executive Vice President and Chief Financial Officer. Prior to Jazz, Mr. Young was an investment banker for nearly 20 years at Barclays Capital, Citigroup, Lehman Brothers, and Merrill Lynch, where he advised and led financings for hundreds of emerging and established life science companies. Additionally, Mr. Young served on the board of PRA Health Sciences (PRAH) until its acquisition by ICON plc for $12 billion in 2021, and currently serves as Lead Independent Director and Chairman of the Audit Committee of CytomX Therapeutics (CTMX) as well as a board member of Alpha-9 Therapeutics and Avenge Bio. Mr. Young holds an MBA and a BS in Economics from the Wharton School of the University of Pennsylvania.
Dr. William has served as Managing Partner and Chief Investment Officer of Logos Capital since its founding in 2019. Prior to founding Logos, Dr. Williams served as an investment professional at Farallon Capital Management. Dr. Williams holds an M.D. from Harvard Medical School where he was a Gerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University.
Noël Brown is the Managing Director and Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, responsible for leading the biotechnology franchise. He has over 20 years of investment banking experience. Noël graduated from the University of Western Ontario and received a law degree from the University of Ottawa and an MBA from the MIT Sloan School of Business.